Capricor Therapeutics Inc Phase 3 Hope 3 Program Update Transcript - Thomson StreetEvents

Capricor Therapeutics Inc Phase 3 Hope 3 Program Update Transcript

Capricor Therapeutics Inc Phase 3 Hope 3 Program Update Transcript - Thomson StreetEvents
Capricor Therapeutics Inc Phase 3 Hope 3 Program Update Transcript
Published Sep 29, 2023
Published Sep 29, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of CAPR.OQ conference call or presentation 29-Sep-23 12:30pm GMT

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Capricor Therapeutics Inc
Ticker
CAPR.OQ
Time
12:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Aydin Huseynov - Ladenburg Thalmann & Co. Inc. - Analyst : Good morning, everyone. Good morning, Linda, AJ. Congratulations with the great progress. Sorry for the background noise here. So want to clarify, regarding the reasons for the dropouts, could you just clarify this? And how these dropouts will compare to other Duchenne trials, if you could, at all, compare to this? Thank you.

Question: Aydin Huseynov - Ladenburg Thalmann & Co. Inc. - Analyst : Thank you, appreciate that. And could you comment on any interactions you may have had with the European agency at all?

Question: Aydin Huseynov - Ladenburg Thalmann & Co. Inc. - Analyst : Got it, got it. And the last one, so I'm just trying to understand what you guys will do beyond (technical difficulty) drug --

Question: Aydin Huseynov - Ladenburg Thalmann & Co. Inc. - Analyst : I'm sorry, could you hear me now?

Question: Aydin Huseynov - Ladenburg Thalmann & Co. Inc. - Analyst : Yeah, so, yes, yeah, so the question is, any plans beyond Duchenne, with your specific drug? Thank you.

Question: Aydin Huseynov - Ladenburg Thalmann & Co. Inc. - Analyst : Perfect, thanks so much for taking my questions. And congratulations with this progress, with clarifying the FDA path, this is significant for me. Thank you so much.

Table Of Contents

Capricor Therapeutics Inc Q3 2024 Earnings Call Transcript – 2024-11-13 – US$ 54.00 – Edited Transcript of CAPR.OQ earnings conference call or presentation 13-Nov-24 9:30pm GMT

Capricor Therapeutics Inc To Discuss DMD Program Update Call Transcript – 2024-09-24 – US$ 54.00 – Edited Transcript of CAPR.OQ conference call or presentation 24-Sep-24 12:30pm GMT

Capricor Therapeutics Inc Q2 2024 Earnings Call Transcript – 2024-08-07 – US$ 54.00 – Edited Transcript of CAPR.OQ earnings conference call or presentation 7-Aug-24 8:30pm GMT

Capricor Therapeutics Inc To Host DMD Program Update Call Transcript – 2024-04-29 – US$ 54.00 – Edited Transcript of CAPR.OQ conference call or presentation 29-Apr-24 12:30pm GMT

Capricor Therapeutics Inc Q3 2023 Earnings Call Transcript – 2023-11-14 – US$ 54.00 – Edited Transcript of CAPR.OQ earnings conference call or presentation 14-Nov-23 9:30pm GMT

Capricor Therapeutics Inc Q2 2023 Earnings Call Transcript – 2023-08-07 – US$ 54.00 – Edited Transcript of CAPR.OQ earnings conference call or presentation 7-Aug-23 8:30pm GMT

Capricor Therapeutics Inc Q1 2023 Earnings Call Transcript – 2023-05-11 – US$ 54.00 – Edited Transcript of CAPR.OQ earnings conference call or presentation 11-May-23 8:30pm GMT

Capricor Therapeutics Inc Q4 2022 Earnings Call Transcript – 2023-03-15 – US$ 54.00 – Edited Transcript of CAPR.OQ earnings conference call or presentation 15-Mar-23 8:30pm GMT

Capricor Therapeutics Inc To Present 18-Month Data Results From Ongoing HOPE-2 Open Label Extension Transcript – 2023-01-25 – US$ 54.00 – Edited Transcript of CAPR.OQ conference call or presentation 25-Jan-23 6:00pm GMT

Capricor Therapeutics Inc Q3 2022 Earnings Call Transcript – 2022-11-10 – US$ 54.00 – Edited Transcript of CAPR.OQ earnings conference call or presentation 10-Nov-22 9:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Capricor Therapeutics Inc Phase 3 Hope 3 Program Update Transcript" Sep 29, 2023. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Capricor-Therapeutics-Inc-Phase-3-Hope-3-Program-Update-T15759940>
  
APA:
Thomson StreetEvents. (2023). Capricor Therapeutics Inc Phase 3 Hope 3 Program Update Transcript Sep 29, 2023. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Capricor-Therapeutics-Inc-Phase-3-Hope-3-Program-Update-T15759940>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.